Biotech's future isn't about higher prices—it's about global scale and prevention. The industry's old playbook is broken. Two structural shifts are reshaping what comes next. New piece from our CEO Brian Finrow and Kevin Klowden in BioCentury: tinyurl.com/2um67p3m

Why can't we solve antibiotic resistance? Economics. Even FDA-approved drugs fail commercially. Preventive antimicrobials change the game—stopping infections before they start creates sustainable market economics while improving patient care. pharmatimes.com/magazine/2025/…

Welcome David Saunders, MD, MPH! U.S. Army Colonel & clinical trialist bringing key expertise as we advance LMN-201 to commercialization. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics

Congrats to Kole Krieger on his promotion to SVP! His leadership is key as we prep for LMN-201's launch. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics

Congrats to Nhi Khuong, PhD on her promotion to EVP! Her leadership advancing our biologics platform is crucial as we prep for LMN-201's launch. https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics

Welcoming Jeff Raikes to our board! https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics

Welcoming Erik Anderson as Vice Chairman! The WestRiver Group & Singularity University CEO led our Series C and will help scale our spirulina-based biologics.

How can U.S. drug research maintain its competitive edge? Our CEO Brian Finrow, in collaboration with Sandeep Patel, explores solutions for accelerating American innovation. Read their analysis here, published in @statnews.com. www.statnews.com/2025/06/03/u...

Our CEO Brian Finrow recently sat down with The Bio Report to discuss how Lumen is revolutionizing biologics production using algae (spirulina). Listen to the full episode here: www.podbean.com/pw/pbblog-e7...

Promising news for C. diff patients! 100% of patients with LMN-201 + antibiotics successfully resolved their primary infection, and 95% of participants had no recurrence within 28 days (RePreve Trial sentinel cohort results). www.lumen.bio/2025/04/02/l... #MedSky